Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Running title : Azacitidine in autoimmune disorders associated with MDS / CMML
暂无分享,去创建一个
O. Decaux | P. Fenaux | C. Gardin | A. Aouba | J. Rossignol | O. Lortholary | Sophie Park | T. Braun | A. Mékinian | O. Fain | J. Arlet | J. Kahn | Anne-Laure Buchdahl | G. Denis | M. Omouri | E. Grignano | É. Liozon | J. Fraison | G. Maigné | N. Leon | S. Berthier | Kahn Jean-Emmanuel | Mekinian Arsène | Fraison Jean-Baptiste | Grignano Eric | Arlet | Jean-Benoit | Decaux Olivier | Denis Guillaume | Buchdahl Anne-Laure | Omouri Mohamed | Maigne Gwenola | Aouba Achille | Leon Nathalie | Berthier Sabine | Liozon Eric | Park | Sophie | Gardin Claude | Lortholary Olivier | Rossignol Julien | Fenaux Pierre | Fain | Olivier | Braun Thorsten
[1] J. Piette,et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. , 2016, Rheumatology.
[2] J. Mairesse,et al. Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis , 2016, British journal of haematology.
[3] B. Esterni,et al. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities , 2015, American journal of hematology.
[4] S. Scholl,et al. Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5‐azacytidine and literature review , 2014, European journal of haematology.
[5] P. Chevallier,et al. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] L. Rink,et al. Regulation of the Interleukin-6 gene expression during monocytic differentiation of HL-60 cells by chromatin remodeling and methylation. , 2014, Immunobiology.
[7] M. Bagot,et al. Neutrophilic dermatoses as systemic diseases. , 2014, Clinics in dermatology.
[8] Pierre Fenaux,et al. Inflammatory Arthritis in Patients With Myelodysplastic Syndromes , 2014, Medicine.
[9] P. Fenaux,et al. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? , 2013, Best practice & research. Clinical haematology.
[10] C. Nakaseko,et al. Successful treatment by azacitidine therapy of intestinal Behçet’s disease associated with myelodysplastic syndrome , 2013, International Journal of Hematology.
[11] M. Voso,et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study , 2013, Leukemia & lymphoma.
[12] Hiroaki TanakaNaomi,et al. Successful treatment by azacitidine therapy of intestinal Behcet's disease associated with myelodysplastic syndrome , 2013 .
[13] P. Vyas,et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). , 2012, Blood.
[14] D. Albert,et al. Rheumatologic manifestations in myelodysplastic syndrome. , 2012, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[15] F. Atem,et al. Activity of azacitidine in chronic myelomonocytic leukemia , 2011, Cancer.
[16] Sophie Park,et al. The autoimmune manifestations associated with myelodysplastic syndrome respond to 5‐azacytidine: a report on three cases , 2011, British journal of haematology.
[17] P. Wallace,et al. Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells. , 2011, Leukemia research.
[18] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[19] Y. Shoenfeld,et al. Diagnostic criteria in autoimmune diseases , 2008 .
[20] J. Salisbury,et al. Complete response of deep neutrophilic dermatosis associated with myelodysplastic syndrome to 5‐azacytidine , 2007, The British journal of dermatology.
[21] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.